Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of support available to people affected by strokes in West Yorkshire.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS West Yorkshire Integrated Care Board have a dedicated team who are working to implement the National Stroke Service Model. This outlines best practice for stroke care for the National Health Service.
The West Yorkshire and Harrogate Integrated Stroke Delivery Network (ISDN) is currently collaborating with all community stroke teams in the area to transform and improve their services. This work has identified gaps in the current workforce provision and differences across the network that will need resolving so it can deliver the recommended national model by NHS England.
The West Yorkshire and Harrogate ISDN is working with all community stroke teams to develop a long-term strategy to:
- address the shortage of qualified staff;
- reconfigure existing services to continually improve;
- achieve efficiency savings; and
- promote and spread innovative practice throughout the network.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an estimate of the average time taken to diagnose ovarian cancer (a) in West Yorkshire and (b) nationally.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The most recent data for the diagnosis of ovarian cancer in West Yorkshire shows a 23-day average from an urgent referral for suspected cancer to diagnosis. This data is based on median values, taken across a twelve-month period from November 2022 to October 2023 inclusive.
Patients diagnosed with ovarian cancer can be diagnosed via other routes, such as when presenting as an emergency case in an unplanned care setting, or as an incidental finding when referred for another elective condition or suspected abnormality, either urgently or non-urgently. Data for these alternative presentation routes in the format requested is not held.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress her Department has made on consulting on proposed amendments to Part IX of the Drug Tariff; and if she will make an assessment of the potential impact of the proposed amendments on (a) the medical technology ecosystem, (b) innovation relating to the the Life Sciences Vision and (c) the wider UK economy.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
A targeted consultation on Medical Devices in Primary Care: Proposals for updating Part IX of the Drug Tariff-medical devices available for prescribing in primary care was issued on 6 October 2023.
The consultation on Part IX of the Drug Tariff sets out a series of proposals to modernise Part IX of the Drug Tariff. The objectives of the proposals are to ensure Part IX consistently includes devices that are of good quality and effectiveness; ensure that the Tariff product list is refreshed going forward and existing and new products are only adopted or continued to be used if able to demonstrate value to the National Health Service and patients; and update processes on Part IX applications to support the adoption of innovation that can improve patient outcomes and the quality of life for patients.
The consultation was fully closed for responses at 4 January 2024. The Department is considering all the responses before finalising any proposed amendments to Part IX of the Drug Tariff. Therefore, the Department will share a response to the consultation and an updated assessment of the impacts in due course.
In forming the proposals, that have been consulted on, the department has had extensive engagement with industry, the health and care sector, NHS commissioners and patient representative groups. There will be further engagement with these stakeholders for any amendments to Part IX that are taken forward.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress his Department has made on implementing its proposals to Part IX of the Drug Tariff; and what steps he is taking to engage the health and care sector on this work.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
A targeted consultation on Medical Devices in Primary Care: Proposals for updating Part IX of the Drug Tariff-medical devices available for prescribing in primary care was issued on 6 October 2023.
The consultation on Part IX of the Drug Tariff sets out a series of proposals to modernise Part IX of the Drug Tariff. The objectives of the proposals are to ensure Part IX consistently includes devices that are of good quality and effectiveness; ensure that the Tariff product list is refreshed going forward and existing and new products are only adopted or continued to be used if able to demonstrate value to the National Health Service and patients; and update processes on Part IX applications to support the adoption of innovation that can improve patient outcomes and the quality of life for patients.
The consultation was fully closed for responses at 4 January 2024. The Department is considering all the responses before finalising any proposed amendments to Part IX of the Drug Tariff. Therefore, the Department will share a response to the consultation and an updated assessment of the impacts in due course.
In forming the proposals, that have been consulted on, the department has had extensive engagement with industry, the health and care sector, NHS commissioners and patient representative groups. There will be further engagement with these stakeholders for any amendments to Part IX that are taken forward.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Answers of 16 October 2023 to Questions 200120, 200121, 200122 and 200123 on Medial Treatments: Innovation, which criteria within the MedTech Strategy Programme governance structures will be used to assess the range of initiatives.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
A key criterion is clear, meaningful metrics that directly align to the core priorities of the Strategy. We are working with system partners, industry and patient groups and other key stakeholders to develop meaningful metrics for each initiative and for the overall robust evaluation of the strategy.
Our previous answer, which you reference in your question, outlined the range of different initiatives we are progressing. Each initiative is at a different stage of progress and will work up individual, appropriate criteria with their key delivery partners. These will be reported to programme governance structures as they become available.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answers of 16 October 2023 to Questions 200120, 200121, 200122 and 200123 on Medial Treatments: Innovation, which criteria within the MedTech Strategy Programme governance structures will be used to assess the range of initiatives.
Answered by Will Quince
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department for Transport:
To ask the Secretary of State for Transport, what recent progress he has made on updating circular 01/2007 on Use of speed and red-light cameras for traffic enforcement: guidance on deployment, visibility and signing, published by his Department on 31 January 2007.
Answered by Richard Holden - Minister without Portfolio (Cabinet Office)
The Department is currently preparing a revised draft of the circular in light of feedback from a range of key stakeholders, including local government and police force representatives, as to what the guidance should contain. We plan to further engage with interested parties on this revision, with a view to publishing in due course.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment she has made of the impact of the Environment Act 2021 on the level of food recycling by local councils.
Answered by Rebecca Pow - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
Simpler Recycling will significantly increase the tonnage of household and business municipal food waste collected for recycling or composting in England, contributing towards Net Zero. The impact assessment accompanying our 2021 consultation estimated that over two metric tonnes of additional food waste per annum would be separately collected by 2030 under our central scenario for these reforms. These figures are being revised for our Final Impact Assessment on Simpler Recycling which will be published in due course.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to reform the NHS pathway for procurement of innovative medical technology; and when he expects the pathway to deliver timely access to medical technology.
Answered by Will Quince
The Department’s inaugural Medical Technology (MedTech) Strategy was published on 3 February 2023, building on the broader Life Sciences Vision. We are committed to ensuring that the Department utilises innovative MedTech as implementation progresses.
The MedTech Strategy includes a range of initiatives aimed at streamlining the end-to-end innovation pathway, including procurement routes, to expedite patient access to MedTech and boost adoption within the National Health Service.
The Innovative Devices Access Pathway pilot was launched on 19 September 2023. This new pathway will provide multi-partner support for the rapid development of innovative technologies for adoption into the NHS to address unmet clinical needs. More information on the pilot is available at the following link:
https://www.gov.uk/government/publications/the-innovative-devices-access-pathway-idap
The National Institute for Health and Care Excellence will undertake new Multi-Technology Evaluations of technologies in use and at a later stage in their lifecycle. These evaluations will enable comparisons between similar products and support the NHS to make better informed decisions on the right product for the right price.
The Department is working closely with NHS Supply Chain and NHS England to develop a consistent methodology for value-based procurement (VBP). VBP aims to shift procurement decisions away from an emphasis on reducing product costs to working with industry to consider technologies that represent a reduction in total costs within the patient pathway. Timeframes are still being determined.
The Department will consult on updating processes on applications to Part IX of the Drug Tariff to support the adoption of innovation in primary and community care.
The NHS Innovation Service is providing innovators with the resources, tools and support they need to increase the chances of getting their product or idea adopted by the NHS. More information is available at the following link:
We plan to assess the impact of these initiatives through the MedTech Strategy Programme governance structures.
Asked by: Mark Eastwood (Conservative - Dewsbury)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase access to innovative medical technologies through the NHS.
Answered by Will Quince
The Department’s inaugural Medical Technology (MedTech) Strategy was published on 3 February 2023, building on the broader Life Sciences Vision. We are committed to ensuring that the Department utilises innovative MedTech as implementation progresses.
The MedTech Strategy includes a range of initiatives aimed at streamlining the end-to-end innovation pathway, including procurement routes, to expedite patient access to MedTech and boost adoption within the National Health Service.
The Innovative Devices Access Pathway pilot was launched on 19 September 2023. This new pathway will provide multi-partner support for the rapid development of innovative technologies for adoption into the NHS to address unmet clinical needs. More information on the pilot is available at the following link:
https://www.gov.uk/government/publications/the-innovative-devices-access-pathway-idap
The National Institute for Health and Care Excellence will undertake new Multi-Technology Evaluations of technologies in use and at a later stage in their lifecycle. These evaluations will enable comparisons between similar products and support the NHS to make better informed decisions on the right product for the right price.
The Department is working closely with NHS Supply Chain and NHS England to develop a consistent methodology for value-based procurement (VBP). VBP aims to shift procurement decisions away from an emphasis on reducing product costs to working with industry to consider technologies that represent a reduction in total costs within the patient pathway. Timeframes are still being determined.
The Department will consult on updating processes on applications to Part IX of the Drug Tariff to support the adoption of innovation in primary and community care.
The NHS Innovation Service is providing innovators with the resources, tools and support they need to increase the chances of getting their product or idea adopted by the NHS. More information is available at the following link:
We plan to assess the impact of these initiatives through the MedTech Strategy Programme governance structures.